SADDLE BROOK, N.J., Jan. 6, 2011 /PRNewswire/ — The FDA’s nod
to a new testosterone gel for men will expand the options they have
to address the problems of sexual dysfunction. “So where does this
leave women?” asks Rachel Braun Scherl, president of Semprae
Laboratories, Inc. The announcement of the approval of Fortesta
comes just months after the FDA’s unanimous rejection of
Flibanserin. Dubbed the “pink pill,” the female Viagra equivalent,
many thought it would be the game changer in closing the gender gap
among the sexes.
While Braun Scherl maintains that she credits the men’s sexual
enhancement category in heightening overall awareness of sexual
health, she believes the time has come for culture and network
executives to acknowledge women’s sexuality.
“Women’s sexual well-being is equally important, and they are
entitled to sexual pleasure. Close to half of all women
report some form of sexual concern, according to statistics from
the American Medical Association,” she says.
Yet, decades after the introduction of Viagra and Cialis, she
maintains, women still don’t have as many options…and culture and
advertisers lag behind in giving women’s sexual satisfaction the
same level of acceptance as men’s sexual needs.
Braun Scherl and her business partner, CEO Mary Wallace Jaensch,
market Zestra® Essential Arousal Oils™, a clinically
proven, hormone-free breakthrough for women documented in two peer
reviewed, published studies to boost women’s libido, increase
arousal and improve overall satisfaction. While many health
professionals enthusiastically recommend it for patients with
dulled desire, advertisers have been reluctant to accept
commercials for this topically applied, safe and effective gel.
If they do agree to air Zestra commercials, airtime is often
restricted to limited early morning hours.
Meantime, maintains Wallace Jaensch, TV spots for men’s sexual
erectile dysfunction products